SkyCell has partnered with Japan Airlines Cargo (JAL Cargo) to meet the country’s growing needs for vaccine and pharmaceutical transportation.
SkyCell is working with JAL Cargo to offer a tailor-made solution that meets the airline’s growing business needs across vaccine and pharmaceutical shipments. This partnership will also see SkyCell further strengthen its presence in Japan and continue to support the temperature sensitive pharmaceutical market with its hybrid containers.
SkyCell’s GDP compliant hybrid containers use lightweight, environmentally friendly material which enables efficiency and reusability. The Swiss engineered hybrid features include shock-absorbent feet to mitigate any breakage during transport and has a double-door system to protect the packing against humidity.
Chiara Venuti, business development director and airline partners, SkyCell, comments: “I see this partnership with JAL as a firm commitment from SkyCell to support the Japanese pharmaceutical market. We play a key role together in delivering life-saving medicine in the most safe, secure, and sustainable way to the patients in need. A great journey starts with small steps, and we look forward to working together with a common mission focused on ensuring patients get the life-saving medicines they need in a sustainable and secure way.”
Hidehiko Umehara, vice president, business promotion department, JAL Cargo comments: “On the signing of a Master Lease Agreement, JAL and SkyCell will work in close co-operation and co-ordination to provide our customers with peace of mind when using SkyCell containers, which have a temperature excursion rate of less than 0.1% and are capable of maintaining the required temperature range at the highest levels, and do not need electric power.”
